EGFR and neoplasm: Possible reasons for resistance to EGFR/EGFRvIII-targeted therapy are blood–brain barrier, tumor heterogeneity, extrachromosomal localization of EGFR, and EGFRvIII amplicons in double minutes, and mutation of genes in downstream pathways [7].